Current perspectives on the recognition and management of treatment-resistant schizophrenia: challenges and opportunities

Expert Review of Neurotherapeutics, Journal Year: 2025, Volume and Issue: unknown

Published: March 31, 2025

Introduction Treatment-resistant schizophrenia (TRS) significantly impacts patients with schizophrenia, leading to a high disease burden, reduced quality of life, and functional impairment. Many fail respond standard antipsychotic treatments, requiring specialized therapeutic approaches. Clozapine remains the only approved treatment for TRS, demonstrating effectiveness in reducing symptoms, hospitalizations, risk suicide. However, its use is often delayed due concerns about adverse events, need ongoing monitoring.

Language: Английский

New pharmacological approaches in the treatment of schizophrenia

Pharmacological Reports, Journal Year: 2025, Volume and Issue: unknown

Published: April 8, 2025

Language: Английский